Post-earnings recap
Reported
Mon, May 8, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
PTC Therapeutics reported a loss that was worse than expected, leading to a significant drop in stock price. Investors reacted negatively due to the lack of revenue information and guidance. The company's ongoing challenges may raise concerns about its future performance and profitability.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.85 | N/A | -11.27% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial performance and did not offer guidance for future quarters. They highlighted ongoing challenges in the market.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability.